title: Is there a need for "triple therapy"? Role of anticoagulation with dual antiplatelet therapy in acute coronary syndromes (ATLAS Study & TRAP Study).
abstract: In the past two decades there has been a succession of advances in the development of anticoagulant and antiplatelet therapies to be used in the treatment of ACS. Despite optimal dual antiplatelet therapy, nearly 10-12 % of patients still face a risk of death or myocardial infarction one year following PCI. This large residual risk provides the impetus for the development of more effective strategies. Dual pathway regimens that combine antiplatelets (aspirin and a thienopyridine), along with an anticoagulant such as rivaroxaban may prove to be a therapeutic option in patients with ACS.
authors.affiliation: PERFUSE Study Group, Beth Israel Deaconess Medical Center, Cardiovascular Division, Department of Medicine, Harvard Medical School, 185 Pilgrim Road, Farr 319, Boston, MA 02215, USA.
authors.forename: William L
authors.initials: WL
authors.lastname: Patrick
authors.forename: Charmaine
authors.initials: C
authors.lastname: Patel
authors.forename: Raviteja
authors.initials: R
authors.lastname: Guddeti
authors.forename: Aarti
authors.initials: A
authors.lastname: Narayan
authors.forename: Michael
authors.initials: M
authors.lastname: Maddaleni
authors.forename: Shankar
authors.initials: S
authors.lastname: Kumar
authors.forename: Kalsang
authors.initials: K
authors.lastname: Dolma
authors.forename: Vishnu Vardhan
authors.initials: VV
authors.lastname: Serla
authors.forename: Maheep
authors.initials: M
authors.lastname: Sangha
authors.forename: Aditya
authors.initials: A
authors.lastname: Govindavarjhulla
authors.forename: Prashanth
authors.initials: P
authors.lastname: Saddala
authors.forename: Priyamvada
authors.initials: P
authors.lastname: Singh
authors.forename: Rim
authors.initials: R
authors.lastname: Halaby
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gibson
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy*; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000502:physiology; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors
references.citation: N Engl J Med. 2001 Aug 16;345(7):494-502
references.pmid: 11519503
references.citation: Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):680-8
references.pmid: 22991347
references.citation: Lancet. 2009 Feb 28;373(9665):723-31
references.pmid: 19249633
references.citation: N Engl J Med. 2009 Sep 10;361(11):1045-57
references.pmid: 19717846
references.citation: Lancet. 2012 Oct 13;380(9850):1317-24
references.pmid: 22932716
references.citation: Blood. 2005 Oct 1;106(7):2329-33
references.pmid: 15947090
references.citation: Circulation. 2003 Jun 17;107(23):2908-13
references.pmid: 12796140
references.citation: Lancet. 1996 Nov 16;348(9038):1329-39
references.pmid: 8918275
references.citation: J Thromb Haemost. 2008 Jan;6(1):104-10
references.pmid: 17944993
references.citation: N Engl J Med. 2012 Jan 5;366(1):9-19
references.pmid: 22077192
references.citation: N Engl J Med. 2005 Mar 24;352(12):1179-89
references.pmid: 15758000
references.citation: BMJ. 2002 Jan 12;324(7329):71-86
references.pmid: 11786451
references.citation: J Thromb Haemost. 2012 Dec;10(12):2470-80
references.pmid: 23083002
references.citation: Circulation. 1992 Jan;85(1 Suppl):I19-24
references.pmid: 1728500
references.citation: N Engl J Med. 1991 May 30;324(22):1565-74
references.pmid: 2027360
references.citation: BMJ. 1998 May 2;316(7141):1337-43
references.pmid: 9563981
references.citation: Circulation. 1994 Jul;90(1):61-8
references.pmid: 8026047
references.citation: Circulation. 2009 Jun 9;119(22):2877-85
references.pmid: 19470889
references.citation: Drug Saf. 1999 Oct;21(4):325-35
references.pmid: 10514023
references.citation: N Engl J Med. 2007 Nov 15;357(20):2001-15
references.pmid: 17982182
references.citation: J Am Coll Cardiol. 1996 May;27(6):1349-55
references.pmid: 8626943
references.citation: N Engl J Med. 1994 Aug 25;331(8):496-501
references.pmid: 8041414
references.citation: Lancet. 2009 Jul 4;374(9683):29-38
references.pmid: 19539361
references.citation: Ann Intern Med. 2005 Aug 16;143(4):241-50
references.pmid: 16103468
references.citation: Stroke. 2006 Feb;37(2):577-617
references.pmid: 16432246
references.citation: J Biol Chem. 1985 Nov 5;260(25):13666-76
references.pmid: 3877053
references.citation: N Engl J Med. 2011 Aug 25;365(8):699-708
references.pmid: 21780946